106 results about "Docosa hexaenoic acid" patented technology

The present invention relates to the Schizochytrium genus SR21 strain and a microorganism belonging to the same species as does said SR21 strain or having substantially the same fungological properties as does said SR21 strain, the said SR21 strain and microorganism having the ability to produce the (n-3) series of docosahexaenoic acid (DHA) and the (n-6) series of docosapentaenoic acid (DPA), and the invention also relates to a process for preparing the (n-3) series of DHA and the (n-6) series of DPA utilizing said microorganisms. The microorganisms according to the present invention are superior in their proliferation character and their propensity to produce fat, and have the ability to produce the (n-3) series of DHA and the (n-6) series of DPA very well. Accordingly, it is possible to effectively produce the (n-3) series of DHA and / or the (n-6) series of DPA, which are useful in the fields of foods and pharmaceuticals, using the microorganisms according to the present invention. In addition, the present invention provides a fat obtained by culturing the present microorganisms. Since the fat composition contains the (n-6) series of DPA in addition to the (n-3) series of DHA having various physiological activities, it is possible to stably and effectively supply the (n-6) series of DPA and / or the (n-3) series of DHA to subjects in need of these highly unsaturated fatty acids by adding the fat composition to various feedstuffs or foods.

The invention relates to an anti-inflaming infant formula milk powder and a preparation process thereof. The anti-inflaming infant formula milk powder comprises the following components in percentage by weight: 22%-50% of lactose, 10%-20% of goat milk whey protein concentrate, 9.8%-20% of structural grease 1,3-dioleoyl 2-palmitoyl triglyceride, 10%-13.5% of non-fat goat milk powder, 8%-10% of vegetable oil, 2%-8% of beta-casein, 0.8%-1.6% of fructooligosaccharides, 0.5%-1.5% of mineral premix, 0.3%-1% of galactooligosaccharide, 0.2%-1% of immunoglobulin G, 0.2%-0.5% of lactulose, 0.10%-0.45% of arachidonic acid, 0.1%-0.6% of docosahexaenoic acid, 0.06%-0.12% of vitamin premix, 0.04%-0.06% of lactoferrin, and 0.01%-0.06% of nucleotide. The invention also includes the preparation process ofthe infant formula milk powder. The nutrition constituents and the functions of the infant formula milk powder are close to those of breast milk, the infant formula milk powder is easy to assimilate,and infants do not get inflamed after eating the milk powder.

The subject invention relates to isolated nucleic acid sequences or genes involved in polyketide synthase (PKS) biosynthetic pathways. In particular, such pathways are involved in the production of polyunsaturated fatty acids (PUFAs) such as, for example, Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA). Specifically, the invention relates to isolating nucleic acid sequences encoding proteins involved in eukaryotic PUFA-PKS systems and to uses of these genes and encoded proteins in PUFA-PKS systems, in heterologous hosts, for the production of PUFAs such as EPA and DHA.

The invention discloses a formula milk powder for promoting the absorption of fatty acid and calcium and a preparation method thereof. Raw cow milk, lactose, 1,3-Dioleoyl 2-palmitoyl triglyceride and demineralized whey powder as main materials are added with concentrated whey albumen powder, Alpha-lactalbumin powder, oligosaccharide, walnut oil, casein phosphopeptide, docosahexaenoic acid, arachidonic acid, nucleotide, lutein, inositol, carnitine and the like as well as vitamins, mineral substances and other nutrients needed for strengthening infants, and fat humanization, protein humanization and carbohydrate humanization are realized. The powdery product is produced by the processes of blending, homogenization, concentration, spray-drying, packaging and the like. According to the physiological characteristics and nutritional demand of the infants, the invention reinforces the calcium, the 1,3-Dioleoyl 2-palmitoyl triglyceride, other nutrient ingredients and the like, and aiming at the oversea clinical test conclusion of the 1,3-Dioleoyl 2-palmitoyl triglyceride, the final test conclusion of comparison with breast milk and infant formula milk powder sold on the market in the process of a clinical feeding test is that the feeding result of the designed formula approximates the feeding result of the breast milk and is better than the feeding result of an infant formula milk powder group sold on the market.

The invention relates to a method for enriching n-3 polyunsaturated fatty acid (n-3PUFA) from fish oil, which belongs to the food organism and functional health product technical field. The method takes the fish oil as a raw material, uses the chemical hydrolysis method to hydrolyze the fish oil, respectively obtains high-purity eicosapentaenoic acid (EPA) and high-purity docosahexaenoic acid (DHA) from the hydrolyzed fish oil through separation and purification, uses glycerol and the purified EPA or DHA as raw materials and utilizes lipase to respectively catalyze and synthesize an EPA glyceride product or a DHA glyceride product in an organic phase. The products are mainly n-3PUFA triglyceride; the purity of the products is high; and the concentration of EPA triglyceride in the EPA glyceride is between 90 and 95 percent, and the concentration of DHA triglyceride in the DHA glyceride is between 92 and 94 percent. The high-purity EPA triglyceride product and the high-purity DHA triglyceride product prepared by the method well improve the application pertinence of different health care efficacies of natural fish oil products and improve the functional health care value of the fish oil products.

The present invention relates to lipid comprising docosapentaenoic acid and / or docosahexaenoic acid preferentially esterified at the sn-2 position of triacylglycerol, and processes for producing and using the lipid.

The present invention belongs to the technical field of feed, and specifically discloses a functional fat feed additive and a preparation method thereof. The functional fatty feed additives mainly comprise the following components in parts by weight: linoleic acid 15-25 parts, arachidonic acid, 2-10 parts, alpha-linolenic acid 8-10 parts, eicosapentaenoic acid 5-10 parts, docosahexaenoic acid 5-10 parts, docosapentenoic acid 2-8 parts, and vitamin C1 1-5 parts. The omega-6 and omega-3 polyunsaturated fatty acid are used to prepare a fat feed additive microcapsule by applying the microencapsulation technique, which not only improves the addition ratio of omega-3 polyunsaturated fatty acid of the daily ration, but also maintains a suitable ratio between omega-6 and omega-3 polyunsaturated fatty acids of the daily ration, makes full use of the nutritional efficacies of omega-6 and omega-3 polyunsaturated fatty acids, improves the immunity of animals, and improves the growth and reproductive performance of animals.

The invention relates generally to phosphopantetheinyl transferases that are required for activation of a polyketide synthase complex to synthesize long chain poly-unsaturated fatty acids (LC-PUFA's) such as docosahexaenoic acid and eicosapentaenoic acid. In particular, the invention relates to bacterial phosphopantetheinyl transferases, DNA constructs for their expression in host cells, and seed, oil and meal when the host cells comprise a plant. Also provided is a method for making a plant oil containing docosahexaenoic acid and / or eicosapentaenoic acid.

The invention relates to a preparation method of DHA (which relates to an unsaturated fatty acid. The invention provides a preparation method of a fully synthetic medium that is suitable for high density growth of fissiparism chytrid and increases the output of the DHA. The DHA comprises a carbon source, amino acids, lysine, inorganic salts, vitamins, trace elements and water. The carbon source is glucose, the amino acids comprise alanine, methionine, cysteine, lysine, histidine, glutamic acid, glutamine, isoleucine, threonine and tryptophan; the vitamins comprise VB1, VB12, biotin, lipoic acid and folic acid; the inorganic salts comprise NaCl, KCl, MgCl2, CaCl2, Na2HPO4 and KH2PO4; and the trace elements comprise AlCl3, H3BO3, ZnSO4, MnCl2, CuSO4, FeSO4 and (NH4)6Mo7O24.4H2O. The synthetic medium is utilized for culturing the fissiparism chytrid based on a shake flask, and the output of the DHA is 9.8g / L.

The present invention provides natural fish oils comprising altered fatty acid profiles, which are useful e.g. as a nutritional supplement. In one aspect, the invention relates to a method for obtaining such fish oils with altered fatty acid profile, in particular, oils containing nutritionally important fatty acids such as Arachidonic acid, Eicosapentaenoic acid and Docosahexaenoic acid. The method comprises the steps of (a) feeding fish a composition comprising at least one fatty acid, so as to obtain altered levels of an endogenous and / or non-endogenous fatty acid in said fish, and (b) extracting oil comprising altered levels of the at least one fatty acid from said fish. The invention further relates to a method of purifying a composition comprising at least one fatty acid by feeding a first composition to a fish and extracting a second composition comprising the at least one fatty acid from said fish. Further aspects of the invention relate to a method of preparing a triglyceride, a method of rearing fish, and use of compositions according to the invention for the preparation of a dietary supplement, a nutraceutical and / or as a food / feed additive. The invention also relates to oils obtainable by the methods of the invention, to fish comprising altered levels of Arachidonic acid, Eicosapentaenoic acid and Docosahexaenoic acid, as well as oil from a fish comprising altered levels of these fatty acids.

The present invention relates to a method for enhancing levels of polyunsaturated fatty acids in thraustochytrid protists and more particularly to a method of enhancing levels of docosahexaenoic acid and eicosapentaenoic acid in cells of thraustochytrid protist belonging to the genera Schizochytrium, Thraustochytrium and Aplanochytrium deposited at The Microbial Type Culture Collection (MTCC), Institute of Microbial Technology, Chandigarh, India under the accession numbers MTCC 5121, MTCC 5122 and MTCC 5123 respectively by growing the same in a medium with increased viscosity, whereby the cells thus enriched in the said polyunsaturated fatty acids (PUFAs) can then be utilized successfully in various beneficial applications that require polyunsaturated fatty acids, such as in animal feeds, human nutrition and extraction of the PUFAs for nutritional supplementation.

An application of refined fur seal oil "OMEGA 3" in preparing the medicines for preventing and treating senile dementia and apoplexy sequela is disclosed. Said defined fur seal oil "OMEGA 3" contains octadecadienoic acid, octadecatrienoic acid, EPA, DPA, DHA, squalene, VE, unsaturated fatty acid, and saturated fatty acid.

Formulations for gastrointestinal administration containing long-chain polyunsaturated fatty acids (PUFAs), such as essentially cholesterol-free arachidonic acid (AA) and docosaccharide, and methods for their preparation are described Hexaenoic acid (DHA). More specifically, the invention relates to methods of reducing the incidence of necrotizing enterocolitis by administering a composition thereby providing n-6 and n-3 long chain PUFAs, phospholipids and / or choline. Compositions from egg yolk lipids are preferred as they contain n-6 and n-3 long chain PUFAs and mainly in the phosphatidylcholine form. Think this provides synergy. Methods of preparing such a composition with improved sensory properties and stability are also provided.

The invention relates to a formula milk powder for students. The formula milk powder for students comprises: 30-50% of whole milk powder, 5-10% of concentrated whey protein powder, 15-30% of desaltedwhey powder, 5-8% of mixed vegetable oil, 5-18% of maltodextrin, 6-12% of white granulated sugar, 0.1-0.5% of phospholipids, 0.09% of a compound vitamin premix, 0.09% of a compound mineral premix, 1.11% of calcium carbonate, 0.8-2.6% of whey protein powder containing alpha-lactalbumin, 0.1-0.5% of DHA powder, 0.1-0.5% of arachidonic acid powder, 1-5% of galacto-oligosaccharide, 1-5% of fructo-oligosaccharide, 0.01-0.1% of animal bifidobacterium animalis Bb-12, 0.05% of a compound nutrition enhancer premix, 0.022% of L-sodium ascorbate, 0-0.1% of lactoferrin, 0-1.2% of phosphatidylserine and 0-0.067% of yeast beta-glucan. In the invention, nutrient elements such as active probiotics, prebiotics GOS, FOS, polyunsaturated fatty acids, vitamin A, vitamin D, iron, zinc, calcium and taurine areparticularly added, and meanwhile, the probiotics are added to promote a balanced immune system; an environment which is not beneficial to the growth of pathogens is created to maintain natural immuneprotection; and the formula milk powder helps to reduce gastrointestinal disorders.

The invention comprises a process of producing polyunsaturated fatty acids from Thraustochytriales at high availability of oxygen by solid state fermentation or submerged fermentation in a batch, semi-continuous or continuous mode. Batch fermentation of more than 200 g / L and up to 450 g / L of dextrose added right in the beginning of fermentation was achieved with productivity of DHA achieved for higher than 10 g / Liter. The process comprises maintaining at least 20% to 30% dissolved oxygen and sometimes up to around 50% or more.

A process for separating polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and eicosapen-taenoic acid (EPA) from less saturated long chain fatty acids (LCFAs) in a lipid composition, wherein said PUFAs and LCFAs are present as (i) triglycerides, or (ii) free fatty acids or monoalkyl esters, by exchange of at least a portion of LCFAs with short and / or medium chain fatty acids (MCFAs). The process can suitably be employed on marine derived oil, marine oil 2 derived oil products and other sources of PUFAs, including PUFA-rich singe cell oils (SCOs), and oils from genetically modified organisms with a modified lipid metabolism. The inventive process is based on novel use of lipases and distillation techniques, selectively chemically modifying species in the substrate material such that the desired species and chemically similar species become sufficiently dissimilar to be separable. Thus PUFA can be effectively enriched from material such as 30 herring oil with low PUFA content and high contant of equal length monounsaturated fatty acids such as 20:1 and 22:1 fatty acids.

In order to obtain infant formula goat milk powder which is more close to breast milk and balanced in nutrition structure, the invention discloses compound grease for simulating breast milk fatty acid, infant formula goat milk powder containing the compound grease and a preparation method of the infant formula goat milk powder, the infant formula goat milk powder containing the compound grease forsimulating the breast milk fatty acid comprises the following components in parts by weight: 150-490 parts of skimmed goat milk powder, 240-520 parts of desalted goat whey powder, 200 to 270 parts ofthe compound grease, 1.8 to 2.2 parts of docosahexaenoic acid, 2.8-3.2 parts of arachidonic acid, 31-33 parts of fructo-oligosaccharide, 2-3.2 parts of a vitamin premix, 1.3-1.6 parts of a mineral premix, 2.5-3.5 parts of calcium carbonate, 0-1 part of tricalcium phosphate, 0.2-0.5 part of l-carnitine, 0.4-0.5 part of nucleotide and 0.04-0.08 part of xanthophyll. The invention relates to the field of infant formula milk powder, the formula goat milk powder disclosed by the invention is obtained by breast milk blending of linolenic acid and linoleic acid, and a plurality of main fats with themost abundant content of the breast milk are subjected to breast milk blending, so that the comprehensive nutrition of infants is guaranteed.

The invention comprises a process of producing polyunsaturated fatty acids from Thraustochytriales at high availability of oxygen by solid state fermentation or submerged fermentation in a batch, semi-continuous or continuous mode. Batch fermentation of more than 200g / L and up to 450 g / L of dextrose added right in the beginning of fermentation was achieved with productivity of DHA achieved for higher than 10g / Liter. The process comprises maintaining at least 20% to 30% dissolved oxygen and sometimes up to around 50% or more.

The present invention refers to a combination of an eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and / or docosahexanoic acid (DHA), or a combination of a nutritional composition comprising EPA, DPA, and / or DHA and a protein, a carbohydrate, a fat, an amino acid, a fatty acid, a dietary fibre, a vitamin, a mineral, a trace element, ß-carotenoid, a flavonoid, a nucleotide, L- carnitin, choline, inositol, taurine, creatine, and / or a co-enzyme, wherein EPA is in an amount of 1 to 1000 mg / 100ml, preferably 100 to 700 mg / 100ml, DPA is in an amount of >50 mg / 100ml, preferably 50 to 1000 mg / 100ml, preferably 6 to 800 mg / 100ml, more preferably 80 to 500 mg / 100ml and / or DHA is in an amount of 1 to 500 mg / 100ml, preferably 1 to 300 mg / 100ml and a chemotherapeutic agent selected from the group consisting of an alkylating drug, an antimetabolite, an antimytotic cytostatic, a topoisomerase inhibitor, antitumor antibiotic, and any other cytostatic, and / or a radiotherapy. These combinations are successful for use in treating a neoplastic disease like the method for treating a neoplastic disease comprising EPA, DPA, and / or DHA or a nutritional composition comprising EPA, DPA, and / or DHA and and a protein, a carbohydrate, a fat, an amino acid, a fatty acid, a dietary fibre, a vitamin, a mineral, a trace element, ß-carotenoid, a flavonoid, a nucleotide, L- carnitin, choline, inositol, taurine, creatine, and / or a co-enzyme in combination with a chemotherapeutic agent, and / or radiotherapy.

The invention relates to the technical field of food, in particular to infant formula milk powder containing inositol and taurine as well as a preparation method of the infant formula milk powder. Theformula milk powder comprises the following raw materials in parts by weight: 20 to 35 parts of whole goat milk powder, 25 to 55 parts of desalted whey powder, 0 to 20 parts of whey protein concentrate powder, 0 to 10 parts of lactose, 5 to 10 parts of 1,3-oleic acid-2-triglyceride palmitate, 3.5 to 15 parts of mixed vegetable oil, 2 to 5 parts of galactooligosaccharide, 0.5 to 1.5 parts of fructo-oligosaccharide, 0.1 to 0.5 part of calcium carbonate, 0.2 to 1 part of a compound mineral, 0.4 to 0.8 part of compound vitamin, 0.1 to 1 part of arachidonic acid (ARA) and 0.1 to 1 part of docosahexaenoic acid (DHA). The formula milk powder is prepared through a certain preparation method. By adopting the infant formula milk powder, the nutritional requirements of the growth and development ofnormal infants can be met completely, and metabolism and intelligence development of the infants can be enhanced; meanwhile, the eyesight, the digestion system and the resistance of the infants can beimproved.

The present invention provides milk powder for improving resistance and promoting growth, and belongs to the technical field of milk powder. The milk powder comprises the following components in partsby mass: 25 to 35 parts of whole milk powder, 25 to 35 parts of demineralized whey powder, 16 to 25 parts of skimmed milk powder, 6-12 parts of isomalto-oligosaccharide, 3-6 parts of concentrated whey protein, 0.1-0.4 part of multivitamins, 0.3-0.8 parts of complex minerals, 0.12-0.25 part of docosahexaenoic acid, 0.12-0.25 part of arachidonic acid, 0.06-0.12 part of yeast beta-glucan, 0.01~0.02part of hydrolyzed egg yolk powder, 0 0.0-0.06 part of lutein, 0.008-0.015 part of N-acetylneuraminic acid and 0.03-0.06 part of probiotics. The milk powder can specifically improve growth ability, intellectual vision, intestinal motility and immunity, is nutritious and comprehensive, and has a pure milk flavor.

The invention discloses nutrient oil for diabetics. The nutrient oil is characterized in that based on the mass for producing 1 ton of the nutrient oil for diabetics, tea oil is used as the main raw material, and the product contains less than 150 Kg of saturated fatty acid, 500-600 Kg of monounsaturated fatty acid, less than 300 Kg of polyunsaturated fatty acid, less than 50 Kg of trans fatty acid and 8-12 Kg of phytosterol. According to the invention, the docosahexaenoic acid, timnodonic acid, arachidonic acid, alpha-linolenic acid and medium-chain saturated fatty acid are enhanced so as to obtain the best ratio (2-3):1 of the n-6 fatty acid to the n-3 fatty acid in the nutrient oil for diabetics and achieve ideal balance among the fatty acids of various structures; and moreover, the phytosterol is added, the product does not contain additive and spice, the processing and storing processes do not contact any chemical solvent, and the product has unique flavor of pure and fresh tea oil and conforms to relevant standards of the state for edible tea oil.

The invention relates to an anti-inflaming infant formula milk powder and a preparation process thereof. The anti-inflaming infant formula milk powder comprises the following components in percentage by weight: 22%-50% of lactose, 10%-20% of goat milk whey protein concentrate, 9.8%-20% of structural grease 1,3-dioleoyl 2-palmitoyl triglyceride, 10%-13.5% of non-fat goat milk powder, 8%-10% of vegetable oil, 2%-8% of beta-casein, 0.8%-1.6% of fructooligosaccharides, 0.5%-1.5% of mineral premix, 0.3%-1% of galactooligosaccharide, 0.2%-1% of immunoglobulin G, 0.2%-0.5% of lactulose, 0.10%-0.45% of arachidonic acid, 0.1%-0.6% of docosahexaenoic acid, 0.06%-0.12% of vitamin premix, 0.04%-0.06% of lactoferrin, and 0.01%-0.06% of nucleotide. The invention also includes the preparation process ofthe infant formula milk powder. The nutrition constituents and the functions of the infant formula milk powder are close to those of breast milk, the infant formula milk powder is easy to assimilate,and infants do not get inflamed after eating the milk powder.

This disclosure relates to methods of inducing adipocyte browning, supporting metabolic flexibility, and / or reducing detrimental WAT deposition or reducing WAT dysfunction in a subject by administering extensively hydrolyzed casein and / or fractions thereof (“eHC”) to the subject, and / or by administering a long chain polyunsaturated fatty acid (e.g., docosahexaenoic acid and / or arachidonic acid) to the subject.

The invention discloses a ceramic tile adhesive mortar which is prepared from the following raw material components in parts by weight: 100 to 120 parts of silicate cement, 20 to 30 parts of lime, 10 to 20 parts of limestone, 15 to 25 parts of sodium carbonate, 20 to 30 parts of clay, 15 to 20 parts of mica powder, 3 to 5 parts of silicon dioxide, 8 to 10 parts of quartz powder, 2 to 5 parts of titanium dioxide, 3 to 5 parts of silicon carbide, 3 to 5 parts of ferric oxide, 2 to 5 parts of docosahexaenoic acid, 1 to 3 parts of sodium carboxymethylcellulose, 2 to 3 parts of hydroxyethyl cellulose, 2 to 5 parts of sodium dodecyl benzene sulfonate, 3 to 5 parts of fatty alcohol-polyoxyethylene ether, 5 to 10 parts of polyvinyl alcohol and 10 to 15 parts of sodium polyacrylate. According to the ceramic tile adhesive mortar, the adhesive property of the mortar is ensured; the cost and the environmental pollution of the ceramic tile adhesive mortar are reduced; the damage to the environment, caused by the application of iron tailings, is avoided.

The invention relates to the technical field of foods, in particular to an infant formula containing choline chloride and L-carnitine and a preparation method thereof. The infant formula comprises thefollowing raw materials in parts by weight: 20 to 35 parts of whole fat goat milk powder, 25 to 55 parts of desalted whey powder, 0 to 20 parts of concentrated whey protein powder, 0.4 to 10 parts oflactose, 3 to 15 parts of mixed vegetable oil, 5 to 10 parts of 1,3-dioleic acid-2-palmitic acid triglyceride, 2 to 4 parts of galactooligosaccharide, 0.5 to 1 part of fructo-oligose, 0.1 to 0.5 partof calcium carbonate, 0.01 to 0.1 part of choline chloride, 0.2 to 1 part of compound minerals, 0.4 to 0.8 part of compound vitamins, 0.4 to 0.8 part of arachidonic acid (ARA) powder, and 0.1 to 1 part of docosahexaenoic acid (DHA) powder, and is prepared by a certain preparation method. The infant formula containing the choline chloride and the L-carnitine satisfies the nutritional needs of thegrowth and development of normal infants and young children, enhances the absorption and digestive functions of infants and young children, and appropriately enhances the mental development of infantsand young children, and is particularly important for maintaining normal metabolism of premature infants whose biochemical functions are still incomplete.

The invention belongs to the technical field of the production of dairy products, and particularly relates to a production method of purely natural DHA (docosa hexaenoic acid) raw milk and an application of the production method. According to the production method of purely natural DHA raw milk, a ration with schizochytrium limacinum powder is fed to cows at the lactation period, so that the content of DHA ingested by the cows is increased; and through autologous metabolism of the cows, natural DHA fresh raw milk stable in production state is transformed. The raw milk has processing characteristics of normal raw milk, and besides, contains certain natural DHA components, in the processing course of subsequent dairy products, later-stage addition of DHA nutrient components is not needed, the problems that peculiar smell is easy to produce in the addition course of product ingredients and the processing technology is complex are solved, and a novel way is opened up for production of purely natural DHA raw milk and dairy products.

The invention relates to the fields of foods and food processing, in particular to beef balls and a preparation method thereof. According to the beef balls disclosed by the invention, beef, butter, isolated protein, starch, zinc gluconate, docosahexenoic acid, a yeast extract, onion powder, olive oil, table salt, white granulated sugar, a dark soy sauce, cooking wine, pricklyash peel powder, chili powder, pepper powder, monosodium glutamate, sodium bicarbonate, phosphate, glutamine aminopherase and D-erythorbic are used as raw materials; and the beef balls are prepared through the technologies of treating the raw materials, performing injection, performing superfine crushing, performing mixing, performing pickling, performing shaping, performing cooking, performing quick-freezing and the like. Through the adoption of the technology disclosed by the invention, zinc and the docosahexenoic acid are uniformly added to the beef balls, the total intaking quantity of human bodies to the docosahexenoic acid can be accurately calculated and controlled through the eating quantity of the beef balls, and finally the purpose of reasonably complementing the zinc and the docosahexenoic acid is realized.

A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and / or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce development defects or disorders associated with Reelin dysfunction or deficiency through the supplemental use of polyunsaturated fatty acids (PUFAs- unsaturated fatty acids having two or more double bonds), and particularly highly unsaturated fatty acids (HUFAs- unsaturated fatty acids having three or more double bonds), and more particularly a HUFA selected from arachidonic acid (ARA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), and even more particularly omega-3 HUFAs, and more particularly DHA, to: compensate for reduced fatty acid binding protein or function thereof in the patient; compensate for reduced brain lipid binding protein or function thereof in the patient; improve the activity of fatty acid binding proteins in the patient.

The current invention describes processes for obtaining of concentrates of esters of eicosapentaenoic acid and docosahexaenoic acid for their use in massive and regular human consumption either as a pharmaceutical ingredient or as a food ingredient, which are characterized by having neutral and stable organoleptic properties, free of side effects, which are typical from marine oils derivatives, and with low content of Persistent Organic Pollutants (POP).